{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,20]],"date-time":"2026-05-20T06:06:56Z","timestamp":1779257216776,"version":"3.51.4"},"reference-count":23,"publisher":"Walter de Gruyter GmbH","issue":"8","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2018,10,25]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:sec id=\"j_jpm-2017-0329_s_999_w2aab3b7c30b1b6b1aab1c16b1Aa\">\n                  <jats:title>Background<\/jats:title>\n                  <jats:p>Despite intensive research, thromboembolism still accounts for significant maternal morbidity and mortality. We examined thrombophilia in patients with thromboembolism during pregnancy and evaluated the efficiency of antithrombotic prophylaxis in patients with thrombophilia for the prevention of recurrent thromboembolism.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec id=\"j_jpm-2017-0329_s_998_w2aab3b7c30b1b6b1aab1c16b2Aa\">\n                  <jats:title>Materials and methods<\/jats:title>\n                  <jats:p>Sixty-eight women with a history of thromboembolism were managed during pregnancy, in light of their thrombotic history and the result of thrombophilia assessment. Group I (n=50) received prophylaxis with low molecular weight heparin (LMWH)\u00b1aspirin (50\u2013100 mg\/day) in preconception period or from the 1<jats:sup>st<\/jats:sup> trimester, during pregnancy and at least 6 weeks postpartum. Group II (n=18) received LMWH\u00b1aspirin from the II to III trimester.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec id=\"j_jpm-2017-0329_s_997_w2aab3b7c30b1b6b1aab1c16b3Aa\">\n                  <jats:title>Results<\/jats:title>\n                  <jats:p>Thromboses were associated with pregnancy in 27 patients (39.7%), with systemic diseases \u2013 in nine (13.2%), oral contraceptives use \u2013 22 (32.3%), immobilization due to surgery and\/or trauma, long flight \u2013 six (8.9%), septic complications \u2013 two (2.9%). Nevertheless, 24.5% of patients had no apparent provoking factor for the development of thrombotic complications. Thirty-seven (54%) patients with venous thromboembolism (VTE) had familial history of VTE, and 25 (36.7%) had personal history of pregnancy complications (fetal loss syndrome, preeclampsia and placental abruption) (P&lt;0.05 vs. control). Thrombophilia was detected in 58 (85.3%). Usual thrombogenic polymorphisms [factor V (FV) Leiden and prothrombin G20210A, heterozygous forms] were revealed in 16 (23.5%) and eight (11.7%) patients, respectively. Antiphospholipid antibodies (aPL) circulation was found in 34 (50%) patients. Non-usual thrombogenic polymorphisms were identified in 44 (64.7%) of the women and hyperhomocysteinemia \u2013 in 30 (44.2%). In group I no one had severe obstetric complications. All the patients were delivered at term and all the babies were alive. In group II moderate-to-severe obstetric complications were noted: preeclampsia \u2013 in 11 (16.2%), severe preeclampsia \u2013 seven (10.3%), preterm delivery \u2013 in 18 (26.4%) patients from subgroup II (P&lt;0.05).<\/jats:p>\n               <\/jats:sec>\n               <jats:sec id=\"j_jpm-2017-0329_s_996_w2aab3b7c30b1b6b1aab1c16b4Aa\">\n                  <jats:title>Conclusions<\/jats:title>\n                  <jats:p>Women with a personal or a family history of thromboembolism and obstetric complications should be screened for thrombophilia. Beginning anticoagulant therapy early in such patients is effective not only for preventing recurring thrombosis but also preventing obstetric complications. Late prophylaxis after the completion of the trophoblast invasion therapy is much less effective.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1515\/jpm-2017-0329","type":"journal-article","created":{"date-parts":[[2018,7,13]],"date-time":"2018-07-13T05:28:32Z","timestamp":1531459712000},"page":"893-899","source":"Crossref","is-referenced-by-count":12,"title":["Thromboprophylaxis in pregnant women with thrombophilia and a history of thrombosis"],"prefix":"10.1515","volume":"46","author":[{"given":"Svetlana","family":"Akinshina","sequence":"first","affiliation":[{"name":"Research Associate of the Ob\/Gyn , Department of The First Moscow State Medical Sechenov University , Moscow , Russia"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alexander","family":"Makatsariya","sequence":"additional","affiliation":[{"name":"Head of Department of Obstetrics and Gynecology #2 of I.M. Sechenov First Moscow State Medical University , Moscow , Russia"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Victoria","family":"Bitsadze","sequence":"additional","affiliation":[{"name":"Department of Obstetrics and Gynecology #2 of I.M. Sechenov First Moscow State Medical University , Moscow , Russia"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jamilya","family":"Khizroeva","sequence":"additional","affiliation":[{"name":"Department of Obstetrics and Gynecology #2 of I.M. Sechenov First Moscow State Medical University , Moscow , Russia"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nadine","family":"Khamani","sequence":"additional","affiliation":[{"name":"Department of Obstetrics and Gynecology #2 of I.M. Sechenov First Moscow State Medical University , Moscow , Russia"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"374","published-online":{"date-parts":[[2018,6,27]]},"reference":[{"key":"2021021318311580597_j_jpm-2017-0329_ref_001_w2aab3b7c30b1b6b1ab2b1b1Aa","unstructured":"Anderson FA Jr, Spencer FA. Risk factors for venous thromboembolism. Circulation. 2003;107:9\u201316."},{"key":"2021021318311580597_j_jpm-2017-0329_ref_002_w2aab3b7c30b1b6b1ab2b1b2Aa","unstructured":"Nicolaides AN, Breddin HK, Carpenter P, Coccheri S, Conard J, De Stefano V, et al. The European Genetics Foundation; The Cardiovascular Disease Educational and Research Trust; The International Union of Angiology; The Mediterranean League on Thromboembolism; Thrombophilia and venous thromboembolism. International consensus statement. Guidelines according to scientific evidence. Int Angiol. 2005;24:1\u201326."},{"key":"2021021318311580597_j_jpm-2017-0329_ref_003_w2aab3b7c30b1b6b1ab2b1b3Aa","doi-asserted-by":"crossref","unstructured":"Simioni P, Tormene D, Spiezia L, Tognin G, Rossetto V, Radu C, et al. Inherited thrombophilia and venous thromboembolism. Semin Thromb Hemost. 2006;32:700\u20138.","DOI":"10.1055\/s-2006-951298"},{"key":"2021021318311580597_j_jpm-2017-0329_ref_004_w2aab3b7c30b1b6b1ab2b1b4Aa","doi-asserted-by":"crossref","unstructured":"Ziakas PD, Poulou LS, Pavlou M, Zintzaras E. Thrombophilia and venous thromboembolism in pregnancy: a meta-analysis of genetic risk. Eur J Obstet Gynecol Reprod Biol. 2015;191:106\u201311.","DOI":"10.1016\/j.ejogrb.2015.06.005"},{"key":"2021021318311580597_j_jpm-2017-0329_ref_005_w2aab3b7c30b1b6b1ab2b1b5Aa","doi-asserted-by":"crossref","unstructured":"Pierangeli SS, Leader B, Barilaro G, Willis R, Branch DW. Acquired and inherited thrombophilia disorders in pregnancy. Obstet Gynecol Clin North Am. 2011;38:271\u201395.","DOI":"10.1016\/j.ogc.2011.02.016"},{"key":"2021021318311580597_j_jpm-2017-0329_ref_006_w2aab3b7c30b1b6b1ab2b1b6Aa","doi-asserted-by":"crossref","unstructured":"Robertson L, Greer I. Thromboembolism in pregnancy. Curr Opin Obstet Gynecol. 2005;17:113\u20136.","DOI":"10.1097\/01.gco.0000162177.30607.59"},{"key":"2021021318311580597_j_jpm-2017-0329_ref_007_w2aab3b7c30b1b6b1ab2b1b7Aa","doi-asserted-by":"crossref","unstructured":"Jackson E, Curtis KM, Gaffield ME. Risk of venous thromboembolism during the postpartum period: a systematic review. Obstet Gynecol. 2011;117:691\u2013703.","DOI":"10.1097\/AOG.0b013e31820ce2db"},{"key":"2021021318311580597_j_jpm-2017-0329_ref_008_w2aab3b7c30b1b6b1ab2b1b8Aa","doi-asserted-by":"crossref","unstructured":"James AH. Thrombosis in pregnancy and maternal outcomes. Birth Defects Res C Embryo Today. 2015;105:159\u201366.","DOI":"10.1002\/bdrc.21106"},{"key":"2021021318311580597_j_jpm-2017-0329_ref_009_w2aab3b7c30b1b6b1ab2b1b9Aa","doi-asserted-by":"crossref","unstructured":"Esteve-Valverde E, Ferrer-Oliveras R, Alijotas-Reig J. Obstetric antiphospholipid syndrome. Rev Clin Esp. 2016;216:135\u201345.","DOI":"10.1016\/j.rce.2015.09.003"},{"key":"2021021318311580597_j_jpm-2017-0329_ref_010_w2aab3b7c30b1b6b1ab2b1c10Aa","doi-asserted-by":"crossref","unstructured":"Simcox LE, Ormesher L, Tower C, Greer IA. Thrombophilia and pregnancy complications. Int J Mol Sci. 2015;16:28418\u201328.","DOI":"10.3390\/ijms161226104"},{"key":"2021021318311580597_j_jpm-2017-0329_ref_011_w2aab3b7c30b1b6b1ab2b1c11Aa","doi-asserted-by":"crossref","unstructured":"Rey E, Kahn SR, David M, Shrier I. Thrombophilic disorders and fetal loss: a meta-analysis. Lancet. 2003;361:901\u20138.","DOI":"10.1016\/S0140-6736(03)12771-7"},{"key":"2021021318311580597_j_jpm-2017-0329_ref_012_w2aab3b7c30b1b6b1ab2b1c12Aa","doi-asserted-by":"crossref","unstructured":"Brenner B. Haemostatic changes in pregnancy. Thromb Res. 2004;114:409\u201314.","DOI":"10.1016\/j.thromres.2004.08.004"},{"key":"2021021318311580597_j_jpm-2017-0329_ref_013_w2aab3b7c30b1b6b1ab2b1c13Aa","doi-asserted-by":"crossref","unstructured":"Bick RL, Frenkel EP, Backer WF, Sarode R. Hematological complications in obstetrics, pregnancy, and gynecology. UK: Cambridge University Press; 2006. p. 604.","DOI":"10.1017\/CBO9780511526978"},{"key":"2021021318311580597_j_jpm-2017-0329_ref_014_w2aab3b7c30b1b6b1ab2b1c14Aa","doi-asserted-by":"crossref","unstructured":"Committee on Practice Bulletins\u2014Obstetrics with the assistance of Charles Lockwood, George Wendel and Neil Silverman, MD. ACOG Practice Bulletin No. 138: Inherited thrombophilias in pregnancy. American College of Obstetricians and Gynecologists women\u2019s health care physicians. Obstet Gynecol. 2013;122:706\u201317.","DOI":"10.1097\/01.AOG.0000433981.36184.4e"},{"key":"2021021318311580597_j_jpm-2017-0329_ref_015_w2aab3b7c30b1b6b1ab2b1c15Aa","doi-asserted-by":"crossref","unstructured":"Bates SM, Greer IA, Middeldorp S, Veenstra DL, Prabulos AM, Vandvik PO. VTE, thrombophilia, antithrombotic therapy, and pregnancy: antithrombotic therapy and prevention of thrombosis, 9th ed: American College of Chest Physicians Evidence-based Clinical Practice Guidelines. Chest. 2012; 141(2 Suppl):e691S\u2013736S.","DOI":"10.1378\/chest.11-2300"},{"key":"2021021318311580597_j_jpm-2017-0329_ref_016_w2aab3b7c30b1b6b1ab2b1c16Aa","doi-asserted-by":"crossref","unstructured":"Palmerola KL, D\u2019Alton ME, Brock CO, Friedman AM. A comparison of recommendations for pharmacologic thromboembolism prophylaxis after caesarean delivery from three major guidelines. Br J Obstet Gynaecol. 2016;123:2157\u201362.","DOI":"10.1111\/1471-0528.13706"},{"key":"2021021318311580597_j_jpm-2017-0329_ref_017_w2aab3b7c30b1b6b1ab2b1c17Aa","doi-asserted-by":"crossref","unstructured":"Romualdi E, Dentali F, Rancan E, Squizzato A, Steidl L, Middeldorp S, et al. Anticoagulant therapy for venous thromboembolism during pregnancy: a systematic review and a meta-analysis of the literature. J Thromb Haemost. 2013;11:270\u201381.","DOI":"10.1111\/jth.12085"},{"key":"2021021318311580597_j_jpm-2017-0329_ref_018_w2aab3b7c30b1b6b1ab2b1c18Aa","unstructured":"Khizroeva JK, Makatsariya AD, Bitsadze VO. Pathogenetic therapy in women with recurrent loss and thrombophilia. 7th World Congress of Perinatal Medicine. J Perinat Med. 2006;33(Supl.1):334."},{"key":"2021021318311580597_j_jpm-2017-0329_ref_019_w2aab3b7c30b1b6b1ab2b1c19Aa","unstructured":"Makatsariya AD, Bitsadze VO, Khizroeva DKh, Akinshina SV. Thromboprophylaxis in pregnant women with a history of thrombophilia and thromboses. Curr Prog Obstet Gynecol. 2013;1:11\u201323."},{"key":"2021021318311580597_j_jpm-2017-0329_ref_020_w2aab3b7c30b1b6b1ab2b1c20Aa","doi-asserted-by":"crossref","unstructured":"Forastiero R, Martinuzzo M. Prothrombotic mechanisms based on the impairment of fibrinolysis in the antiphospholipid syndrome. Lupus. 2008;17:872\u20137.","DOI":"10.1177\/0961203308091633"},{"key":"2021021318311580597_j_jpm-2017-0329_ref_021_w2aab3b7c30b1b6b1ab2b1c21Aa","doi-asserted-by":"crossref","unstructured":"Dossenbach-Glaninger A, van Trotsenburg M, Dossenbach M, Oberkanins C, Moritz A, Krugluger W, et al. Plasminogen activator inhibitor 1 4G\/5G polymorphism and coagulation factor XIII Val34Leu polymorphism: impaired fibrinolysis and early pregnancy loss. Clin Chem. 2003;49:1081\u20136.","DOI":"10.1373\/49.7.1081"},{"key":"2021021318311580597_j_jpm-2017-0329_ref_022_w2aab3b7c30b1b6b1ab2b1c22Aa","doi-asserted-by":"crossref","unstructured":"Glueck CJ, Phillips H, Cameron D, Wang P, Fontaine RN, Moore SK, et al. The 4G\/4G polymorphism of the hypofibrinolytic plasminogen activator inhibitor type 1 gene: an independent risk factor for serious pregnancy complications. Metabolism. 2000;49:845\u201352.","DOI":"10.1053\/meta.2000.6749"},{"key":"2021021318311580597_j_jpm-2017-0329_ref_023_w2aab3b7c30b1b6b1ab2b1c23Aa","doi-asserted-by":"crossref","unstructured":"Koltsova EM, Balandina AN, Grischuk KI, Shpilyuk MA, Seregina E, Dashkevich NM, et al. The laboratory control of anticoagulant thromboprophylaxis during the early postpartum period after cesarean delivery. J Perinat Med. 2018;46:251\u201360.","DOI":"10.1515\/jpm-2016-0333"}],"container-title":["Journal of Perinatal Medicine"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/www.degruyter.com\/view\/j\/jpme.2018.46.issue-8\/jpm-2017-0329\/jpm-2017-0329.xml","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.degruyter.com\/document\/doi\/10.1515\/jpm-2017-0329\/xml","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.degruyter.com\/document\/doi\/10.1515\/jpm-2017-0329\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,4,22]],"date-time":"2021-04-22T01:35:10Z","timestamp":1619055310000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.degruyter.com\/document\/doi\/10.1515\/jpm-2017-0329\/html"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,6,27]]},"references-count":23,"journal-issue":{"issue":"8","published-online":{"date-parts":[[2018,6,27]]},"published-print":{"date-parts":[[2018,10,25]]}},"alternative-id":["10.1515\/jpm-2017-0329"],"URL":"https:\/\/doi.org\/10.1515\/jpm-2017-0329","relation":{},"ISSN":["1619-3997","0300-5577"],"issn-type":[{"value":"1619-3997","type":"electronic"},{"value":"0300-5577","type":"print"}],"subject":[],"published":{"date-parts":[[2018,6,27]]}}}